• Dhrubajyoti Bandyopadhyay, Samantha Sartori, Usman Baber, Davide Cao, Rishi Chandiramani, Didier Tchétché, Anna Sonia Petronio, Julinda Mehilli, Thierry Lefèvre, Patrizia Presbitero, Piera Capranzaro, Gennaro Sardella, Nicolas M Van Mieghem, Jaya Chandrasekhar, Nicholas Dumonteil, Chiara Fraccaro, Daniela Trabattoni, Ghada W Mikhail, Christoph Naber, Annapoorna Kini, Marie-Claude Morice, Bimmer E Claessen, Alaide Chieffo, and Roxana Mehran.
• Icahn School of Medicine at Mount Sinai/Mount Sinai St Luke's Roosevelt, New York, New York.
• Catheter Cardiovasc Interv. 2020 Jul 1; 96 (1): 198-207.

BackgroundThe prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown.MethodsWomen's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2 ); (b) mild CKD (stage 3a CKD: eGFR = 45-59 ml/min/1.73 m2 ); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m2 ). All events were adjudicated according to the Valve Academic Research Consortium (VARC)-2 criteria.ResultOut of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1-year VARC-2 safety endpoints [hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10-2.60], all-cause death (HR 2.00, 95% CI: 1.03-3.90), and composite of death, myocardial infarction, stroke or life-threatening bleeding (HR 1.70, 95% CI: 1.04-2.76). There were no differences in 30-day and 1-year VARC-2 efficacy and 30-day VARC-2 safety outcomes.ConclusionCKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR.© 2020 Wiley Periodicals, Inc.

32 keywords...

hide…